Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644315 · ClinicalTrials.gov registry record · Phase 2
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04644315 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 1 participants.
The verdict
NCT04644315, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
Interventions
- DRUG Alectinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04644315
The ClinicalTrials.gov registry entry for NCT04644315 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alectinib is the first listed.
NCT04644315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04644315 about?
NCT04644315 is a clinical study titled "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors". This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
What is the current status of trial NCT04644315?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-05-24. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04644315?
The interventions under investigation include: Alectinib (DRUG).
Who is sponsoring clinical trial NCT04644315?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.